Gelteq Limited Ordinary Shares (NASDAQ:GELS) — Market Cap & Net Worth
Market Cap & Net Worth: Gelteq Limited Ordinary Shares (GELS)
Gelteq Limited Ordinary Shares (NASDAQ:GELS) has a market capitalization of $5.03 Million ($5.03 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28563 globally and #5798 in its home market, demonstrating a 137.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gelteq Limited Ordinary Shares's stock price $1.14 by its total outstanding shares 10711059 (10.71 Million). Review Gelteq Limited Ordinary Shares debt and liabilities to assess the company's total debt and financial obligations.
Gelteq Limited Ordinary Shares Market Cap History: 2024 to 2026
Gelteq Limited Ordinary Shares's market capitalization history from 2024 to 2026. Data shows change from $24.85 Million to $12.21 Million (-44.02% CAGR).
Index Memberships
Gelteq Limited Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #840 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2678 of 3165 |
Weight: Gelteq Limited Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gelteq Limited Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gelteq Limited Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
51.73x
Gelteq Limited Ordinary Shares's market cap is 51.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $8.57 Million | $165.65K | -$6.65 Million | 51.73x | N/A |
Competitor Companies of GELS by Market Capitalization
Companies near Gelteq Limited Ordinary Shares in the global market cap rankings as of June 18, 2026.
Key companies related to Gelteq Limited Ordinary Shares by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Gelteq Limited Ordinary Shares Historical Marketcap From 2024 to 2026
Between 2024 and today, Gelteq Limited Ordinary Shares's market cap moved from $24.85 Million to $ 12.21 Million, with a yearly change of -44.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.21 Million | +42.50% |
| 2025 | $8.57 Million | -65.52% |
| 2024 | $24.85 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Gelteq Limited Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.03 Million USD |
| MoneyControl | $5.03 Million USD |
| MarketWatch | $5.03 Million USD |
| marketcap.company | $5.03 Million USD |
| Reuters | $5.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.